Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Experiences 47.5% Decline in Short Interest in February

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) experienced a remarkable decrease in its short interest during February. As of February 15th, the total short interest was recorded at 1,460,000 shares. This signified a substantial reduction of 47.5% compared to the January 31st total of 2,780,000 shares. Currently, around 5.9% of the company's shares are being sold short. Given the average daily trading volume of 2,750,000 shares, the short-interest ratio stands at 0.5 days.

Tevogen Bio Stock Performance

The stock of Tevogen Bio opened at $1.28 on Friday. The company has a 50-day moving average price of $1.34 and a 200-day moving average price of $1.13. Over the past year, Tevogen Bio has seen a low of $0.26 and a high of $8.49.

Institutional Inflows and Outflows

Several hedge funds have made changes to their positions in Tevogen Bio recently. China Universal Asset Management Co. Ltd. initiated a new position in the stock during the fourth quarter, valued at approximately $38,000. JPMorgan Chase & Co. increased its stake in Tevogen Bio by 74.2% in the same period and now owns 39,207 shares valued at $40,000 after adding 16,695 shares. Barclays PLC also raised its stake by 39.2% during the fourth quarter, owning 45,600 shares valued at $48,000 after acquiring an additional 12,847 shares. Another player, XTX Topco Ltd., bought a new position in Tevogen Bio estimated at about $55,000 during this period. Additionally, Northern Trust Corp increased its stake by 13.0%, holding a total of 118,415 shares valued at $122,000 after acquiring 13,595 additional shares.

About Tevogen Bio

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy firm focused on developing off-the-shelf precision T cell therapies. These therapies target the treatment of various conditions including infectious diseases, cancers, and neurological disorders. One of the company's key products, TVGN 489, has successfully completed its Phase 1 clinical trial aimed at treating and preventing prolonged symptoms following COVID-19 (referred to as Long COVID) in immune-compromised patients as well as the elderly and those on T cell suppressing medications.

Related Articles

• Five stocks we like better than Tevogen Bio
• Stock Sentiment Analysis: How it Works
• Autodesk Designs Value for Investors: Uptrend Set to Continue
• How to Plot Fibonacci Price Inflection Levels
• Anheuser-Busch Stock Rallies—Is the King of Beers Back?
• What is Insider Trading? What You Can Learn from Insider Trading
• MarketBeat Week in Review – 02/24 - 02/28

Tevogen, Stocks, Market